Cowen and Company’s Mesoblast MESO Stock Holding History

Cowen and Company’s Portfolio MESO Stock Details MESO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-28,650	Closed	-$429K	–	662
2021 Q2	$429K	Sell	28,650 -45,850	-62%	-$720K	0.02%	199
2021 Q1	$1.23M	Sell	74,500 -25,000	-25%	-$472K	0.08%	125
2020 Q4	$1.69M	Sell	99,500 -30,500	-23%	-$751K	0.15%	55
2020 Q3	$4.83M	Buy	+130,000	New	+$4.07M	0.79%	23

Other funds holding MESO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Cowen and Company's MESO Position: Q3 2021 in Review

Cowen and Company sold out of Mesoblast (MESO) in Q3 2021, closing a stake of 28,650 shares — an estimated $429K sold.

Cowen and Company first reported a position in MESO in Q3 2020 and held it in 4 quarters. The position peaked at $4.83M in Q3 2020. 41 funds tracked by Wall St. Rank hold MESO as of Q3 2021.

Cowen and Company reported no remaining Mesoblast position as of Q3 2021 after selling out during the quarter.
Cowen and Company sold 28,650 Mesoblast shares in Q3 2021, an estimated $429K.
Cowen and Company first reported a position in Mesoblast in Q3 2020 and held it in 4 quarters.
Cowen and Company's Mesoblast position peaked at $4.83M in Q3 2020.
41 funds tracked by Wall St. Rank held Mesoblast as of Q3 2021.

Based on Cowen and Company's 13F filing for Q3 2021, filed 12 Nov 2021.